Biogen is a successful biotechnology company faces a critical moment. CEO John Mullen ponders how technological changes in the study of functions will form large enterprise solutions. This is a world in which biotech companies work has changed dramatically over the past few years. Part of biology were growing rapidly on the individualistic, wet lab bench science driven field to one where scientists manipulate large amounts of data and to share research factorylike steps in the production process. At the same time, the cost of drug development and bringing to market ballooned from about $ 231 million in 1991 to $ 802 million in 2000. Biogen were conservative in adopting new genomics. This case describes how the company has decided to bring into the house last genomics tools silicon and applied them to the discovery and research phase of drug development. In addition, the company then restructured its research strategy. As new tools and early-phase studies have begun to bear fruit, Mullen realized that they involve significant changes in the future for other parts of Biogen. "Hide
by Juan Enriquez, Gary P. Pisano, Gay L. Bock Source: Harvard Business School 30 pages. Publication Date: April 9, 2002. Prod. #: 602122-PDF-ENG
